KayHian Sekuritas

Country Daily | Indonesia

Wednesday, 18 November 2026



Key Indices

	Prev Close	1D %	1W %	1M %	YTD %
DJIA	50759.4	(1.6)	(2.8)	(2.4)	5.6
S&P 500	7340.5	(1.0)	(2.4)	(4.2)	7.2
FTSE 100	10689.9	(1.8)	(0.6)	(1.8)	7.6
AS30	8997.3	(1.8)	(3.2)	0.6	(0.2)
CSI 300	3976.5	(0.1)	(2.0)	(4.7)	(14.1)
FSSTI	5109.1	(1.4)	(2.8)	(5.7)	10.0
HSCEI	7904.4	(1.0)	(4.4)	(2.8)	(11.3)
HSI	23508.2	(1.0)	(4.3)	(2.8)	(8.3)
JCI	5304.8	(0.3)	3.5	2.3	(38.7)
KLCI	1575.2	(0.8)	(1.8)	(2.0)	(6.2)
KOSPI	4968.5	(2.6)	(5.2)	(12.3)	17.9
Nikkei 225	58860.4	(1.3)	(2.6)	(9.9)	16.9
SET	1474.7	(1.7)	(1.4)	(6.3)	17.1
TWSE	40092.1	(2.3)	(6.1)	(14.9)	38.4
BDI	2893	(1.0)	1.1	15.2	54.1
CPO (RM/mt)	4239	1.7	3.4	(4.8)	7.8
Brent Crude (US$/bbl)	93	1.1	2.1	(14.9)	53.6

Source: Bloomberg

Corporate Events

	Venue	Begin	Close
Analyst Marketing by Johnny Yum on GC AI Sector	Taipei	17 Nov	18 Nov
Corporate Roadshow with NTT DC REIT (NTTDCR SP)	Bangkok	23 Nov	23 Nov
Corporate Roadshow with NTT DC REIT (NTTDCR SP)	Kuala Lumpur	25 Nov	25 Nov
Virtual Analyst Presentation by Jonathan Koh on S-REITs Results Wrap	Singapore	25 Nov	25 Nov
Regional 1H2027 Strategy Conference	Malaysia	02 Dec	02 Dec

Top Stories

Sector Update | Heathcare Page 2 →

- MIKA and HEAL trade below their five-year -2SD EV/EBITDA bands, while 9M26 EBITDA grew 8.2% at MIKA and 17.8% at SILO as stronger revenue intensity cushioned softer volumes. Nevertheless, declining capacity utilisation and rising capital intensity remain concerns. We retain our 2027 earnings forecasts, although downside risks remain. Maintain OVERWEIGHT, primarily on valuation grounds. We prefer MIKA for its specialty-care capabilities and strong profitability, and add KLBF for its volume-led growth. Both offer strong net cash positions.

Technical Analysis

Telkom Indonesia | TLKM IJ Page 5 →

- Trading Buy Range: We have a technical Buy at Rp2,180, and take profit at Rp2,340.

Bank Syariah Indonesia | BRIS IJ Page 5 →

- Trading Buy Range: We have a technical Buy at Rp1,220, and take profit at Rp1,280.

Disclaimer: In Traders' Corner, technical analysis is carried out purely based on charting patterns, price movements and trends, and is thus independent of the fundamental research views of our analysts. As a result, and from time to time, we may make a technical recommendation that is opposite to our fundamental BUY/HOLD/SELL rating.

Healthcare

Acuity Cushions Soft Volumes; Valuations Offer Opportunity

Highlights

- **Revenue intensity cushions softer volumes**. MIKA's high-complexity revenue grew 25.2% yoy, while SILO's revenue per inpatient day rose 10.2%, supporting net profit growths of 6.7% and 22.1%, respectively. HEAL lagged, with revenue per inpatient day declining 1% and its out-of-pocket segment contracting 18.8%.
- **Asset productivity and capital efficiency become increasingly important**. HEAL's bed capacity expanded 8.2% against a 3.2% growth in inpatient days, while MIKA's ROIC excluding landbank declined to 37.9% from 42.4%. SILO's net gearing rose to 55.2% from 4.8% following its hospital property acquisitions.
- **Maintain OVERWEIGHT; prefer MIKA and KLBF**. Depressed valuations offer attractive opportunities despite earnings uncertainty. MIKA offers established specialty-care capabilities, strong profitability and Rp2.7t in net cash, while KLBF provides exposure to volume-led growth, market-share gains and a Rp5.3t net cash position.

Analysis

- **Demand is turning selective: volume is soft, acuity is holding.** In 9M26, inpatient admissions fell 3.6% yoy at Mitra Keluarga Karyasehat (MIKA), driven by softer National Health Insurance (BPJS) patient volume, while Medikaloka Hermina (HEAL) and Siloam International Hospitals (SILO) recorded modest inpatient admission growth of 3.2% and 2.0%. Beyond tighter BPJS referral controls, softer household spending appears to be contraining self-funded healthcare spending with HEAL's out-of-pocket segment contracting 18.8% yoy (vs +22.4% growth in its insurance and corporate segment). While patients may increasingly defer less urgent treatments, demand for higher-complexity care appers relatively resilient. This is reflected in MIKA's 25.2% growth in high-complexity revenue. We see an increasing shift from volume-driven towards acuity and case mix-led growth, favouring operators with established speciality-care capabilities.
- **Revenue intensity carrying earnings, but conversion varies across operators.** In 9M26, the strong growth from high-complexity revenue lfited the segment contritbution to revenue to 28% (vs 9M24: 24%), while SILO's revenue per patient day rose 10.2%. The stronger revenue intensity supported 8.2% MIKA's EBITDA growth of 8.2% and SILO's 17.8%, translating into net profit growths of 6.7% and 22.1% respectively. In contrast, HEAL's revenue per inpatient day declined 1%, despite rising revenue contribution from non-BPJS patients. While stronger revenue intensity cannot indefinitely compensate for weak utilisation, the earnings resilience at MIKA and SILO challenges the narrative of a sector in structural earnings decline.
- **Slower demand growth puts greater emphasis on asset productivity.** In 9M26, HEAL expanded its bed capacity by 8.2% against just a 3.2% growth in inpatient days, while MIKA's inpatient days fell 6% despite a 1.6% capacity increase. Consequently, HEAL's bed occupancy rates (BOR) fell by 3.7ppt to 67.9% and MIKA's BOR dropped 4.2ppt to 52.6%, while SILO's remained broadly stable at 62.5%. The trade-off between expansion and shareholder returns is becoming increasingly evident - MIKA's ROIC (excluding landbank) fell to 37.9% from 42.4%, higher depreciation drove HEAL's 14.8% yoy net profit decline in 9M26, and SILO's hospital property acquisitions materially increased its financial leverage, with net gearing ratio rising to 55.2% at end-Sep 26 from 4.8% at end-25.

Analyst(s)

Posmarito Pakpahan
posmarito@kh.co.id
+6221 2993 3990

OVERWEIGHT (Maintained)

Sector Picks

Ticker	Rec	Share Price (Rp)	Target Price (Rp)
KLBF	BUY	790	1,000
MIKA	BUY	1,375	1,900


Source: Bloomberg, UOB Kay Hian

MIKA's EV/EBITDA




Source: Bloomberg, UOB Kay Hian

HEAL's EV/EBITDA



Source: Bloomberg, UOB Kay Hian

FCF Yield



Source: Bloomberg, UOB Kay Hian

Valuation

Ticker	Rec	Price 17 Nov 26 (Rp)	Target Price (Rp)	Market Cap (Rpb)	PE 2026F (x)	PE 2027F (x)	EV/EBITDA 2026F (x)	EV/EBITDA 2027F (x)	Div Yield 2026F (%)	Div Yield 2027F (%)	ROE 2027F (%)
MIKA	BUY	1,375	1,900	19,122	13.2	11.9	7.8	7.9	3.4	3.8	18.6
HEAL	BUY	505	785	7,759	17.7	15.2	6.4	5.8	1.9	2.1	8.0
SILO	NR	1,480	n.a.	19,249	16.0	15.5	8.1	6.8	2.4	2.8	10.8
KLBF	BUY	790	1,000	36,982	9.9	9.0	6.1	5.7	4.5	5.2	15.0

Source: Bloomberg, UOB Kay Hian

Valuation/Recommendation

- **Trading at below -2SD, reflecting significant earnings and market-related concerns.** Moderating growth, lower capacity utilisation and declining capital efficiency warrant lower valuation multiples than historical averages. However, the extent of the de-rating suggests that some of anticipated deterioration in fundamentals may already be reflected invaluations. MIKA and HEAL are currently trading below -2SD to their five-year mean EV/EBITDA, with broader market weakness and MSCI-related uncertainty putting further pressure on pressures. Notably, MIKA, HEAL and SILO are no longer represented in the MSCI, limiting their exposures to direct MSCI-related passive selling.
- **Maintain OVERWEIGHT; prefer MIKA for acuity and balance sheet, add KLBF as the diversifier.** Our sector recommendation is primarily valuation driven, with MIKA trading at 7.9x 2027F EV/EBITDA and KLBF trading at 9.0x 2027F PE. Both companies offer established franchises, strong profitability and net cash balance sheets, with the financial capacity to fund future growth internally. MIKA (BUY/Target: Rp1,900) offers attractive exposure to an established hospital franchise with an EBITDA margin of 39.2% and a Rp2.7t net cash position. Its ability to sustain earnings growth despite declining patient volumes reflects its established speciality-care capabilities and favourable payer mix. Beyond hospitals, KLBF (BUY/Target: Rp1,000) offers exposure to different source of earnings growth. Its 11.5% yoy revenue growth in 9M26 was largely volume-driven, supported by market-share gains, while tighter cost control sustained earnings growth despite raw material cost and currency pressures. Its diversified product portfolio, established market leadership and Rp5.3t net cash position underpin its earnings resilience.


Earnings Revision

- **No change to our 2027 forecasts, although downside risks remain.** We retain our existing hospital earnings forecast as 9M26 results were within expectations and management teams have yet provide 2027 guidances. However, we see limited evidence of a meaningful patient-volume recovery amid softer household purchasing power, tighter BPJS referral controls, and stricter private insurer reimbursement. The ability to monetise existing capacity and contain operating costs will be critical to meeting our 2027 earnings forecasts.
- **Revenue intensity remains the key earnings cushion.** In the absence of meaning of meaningful volume recovery, we expect higher treatment complexity and a more favaourable payer mix to remain important growth drivers in 2027. MIKA is particularly well positioned given its established specialty-care capabilities, higher private revenue contribution (90%) and strong net cash position. While higher depreciation could weigh on earnings across hospital operators, HEAL and SILO face additional pressure from higher financial leverage.

Sector Catalyst/Risk


- **Catalysts:** a) Greater visibility on 2027 earnings, b) stabilisation in hospital capacity utilisation while sustaining revenue intensity, c) greater clarity on

Bed Occupancy Rate (BOR)




Source: Respective companies, UOB Kay Hian

Number Of Beds And Patient Volumes




Source: Respective companies, UOB Kay Hian

Patient Volume And Revenue Intensity



Source: Respective companies, UOB Kay Hian

Net Gearing Ratio




Source: Respective companies, UOB Kay Hian

BPJS referral policies and reimbursement, d) rupiah stabilisation, and e) resolution of MSCI-related uncertainty.

- **Risks:** a) Prolonged utilisation weakness, b) tighter reimbursement, c) falling returns on increamental capacity, d) further country-risk-driven de-rating, e) regulatory of drug pricing control beyond BPJS patients, and f) rupiah depreciation.
- **Continued government support for BPJS**. The government's Rp10t funding injection in Oct 26, with a further Rp10t earmarked subject to evaluation, underscores its commitment to sustaining the BPJS programme. While structural funding challenges remain, the additional funding should ease near-term liquidity pressure and support hospitals' cash collection, particularly for operators with higher BPJS exposure.

Account Receivable Days



Source: Respective companies, UOB Kay Hian

Technical Analysis

Analyst(s)

Maskun Ramli, CFTe
maskunramli@kh.co.id
+6221 2993 3915



Source: Tradingview

Telkom Indonesia
TLKM IJ

Technical BUY with 7% potential return

Resistance:	Rp2,340, Rp2,440
Support:	Rp2,120, Rp2,020
Stop-loss:	Rp2,110

Share price closed unchanged and formed a neutral candlestick. Momentum is looking positive; hence, we see potential for rallies ahead and challenge the resistance at Rp2,340 and Rp2,440. The RSI is holding well above its midline, while the MACD remains on a bullish crossover. Buy at Rp2,180 and take profit at Rp2,340.

Approximate timeframe: 2-4 weeks.

Our institutional research has a fundamental BUY and target price of Rp3,300.



Source: Tradingview

Bank Syariah Indonesia
BRIS IJ

Technical BUY with 5% potential return

Resistance:	Rp1,280, Rp1,325
Support:	Rp1,200, Rp1,100
Stop-loss:	Rp1,160

Share price closed with strong gains and formed a long-body bullish candlestick. Price broke above its Rp1,200 resistance level; hence, it could trigger more rallies and challenge the resistance at Rp1,280 and Rp1,325. The RSI is sloping upwards and is above its midline, while the MACD remains on a bullish crossover. Buy at Rp1,220 and take profit at Rp1,280.

Approximate timeframe: 2-4 weeks.

Our institutional research has a fundamental BUY and target price of Rp3,300.

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at this link or by scanning the QR code below:

The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."